Welcome to our dedicated page for Diamedica Therapeutics news (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on Diamedica Therapeutics stock.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical-stage biopharmaceutical company whose news flow centers on the development of DM199, a recombinant KLK1 protein candidate for preeclampsia, fetal growth restriction and acute ischemic stroke. Company updates frequently highlight progress in its clinical trials, regulatory interactions and financing activities that support these programs.
Investors following DMAC news can expect detailed reports on the Phase 2 investigator-sponsored trial of DM199 in preeclampsia, including interim data on blood pressure reduction, uterine artery blood flow and placental transfer findings. DiaMedica also issues news about the multi-part design of this trial, expansion cohorts, and plans to evaluate DM199 in women with early-onset fetal growth restriction.
Another major news theme is the ReMEDy2 Phase 2/3 trial in acute ischemic stroke, where DiaMedica provides enrollment updates and guidance on the timing of interim analyses. Regulatory milestones, such as the in-person pre-IND meeting with the U.S. Food and Drug Administration for a planned U.S. Phase 2 preeclampsia study and related non-clinical study requirements, are also covered in company press releases.
DiaMedica’s news feed additionally includes quarterly financial results, descriptions of its cash runway in relation to planned clinical studies, private placements and at-the-market offering arrangements. Corporate developments, such as participation in healthcare investor conferences, inducement equity grants and executive appointments in clinical leadership roles, appear regularly. For readers tracking DMAC, this news page offers a consolidated view of clinical, regulatory, financial and corporate announcements related to the company’s efforts in preeclampsia, fetal growth restriction and acute ischemic stroke.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its first quarter 2024 financial results on May 8th, followed by a business update and live conference call on May 9th. The company focuses on developing recombinant KLK1 (DM199) for acute ischemic stroke treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.